dextroamphetamine and Narcolepsy studies

Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.

Narcolepsy: A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)

Research Excerpts

Excerpt	Relevance	Reference
"Five patients with narcolepsy (four with the allied symptom of cataplexy) were treated with the serotonin antagonist methysergide."	7.65	Methysergide in the treatment of narcolepsy. ( Troupin, AS; Wilkus, RJ; Wyler, AR, 1975)
"Cataplexy was not affected by amphetamine treatment, but was abolished in two patients when clomipramine was given together with either amphetamine."	6.64	Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy. ( Fenton, GW; Parkes, JD, 1973)
"Selegiline was compared to no treatment (7 subjects) or conventional central stimulant drugs, including dexamphetamine or mazindol (14 subjects)."	5.27	Selegiline in narcolepsy. ( Jenner, P; Langdon, N; Lock, CB; Parkes, JD; Roselaar, SE, 1987)
"Patients (N=151) with narcolepsy who had been unsatisfactorily treated with dextroamphetamine (N=48), methylphenidate (N=66), or pemoline (N=37) were enrolled in this 6-week, open-label, multicenter study."	5.10	Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. ( Feldman, NT; Fry, JM; Harsh, J; Schwartz, JR, 2003)
" Methylphenidate hydrochloride ('Ritalin') was the prescribers' most popular agent and 'narcolepsy' was the most frequently cited clinical indication for psychostimulants."	3.70	Psychostimulants and psychiatrists: the Trent Adult Psychiatry Psychostimulant Survey. ( Bramble, D, 2000)
"Five patients with narcolepsy (four with the allied symptom of cataplexy) were treated with the serotonin antagonist methysergide."	3.65	Methysergide in the treatment of narcolepsy. ( Troupin, AS; Wilkus, RJ; Wyler, AR, 1975)
"The clinical symptoms of cataplexy, sleep paralysis, hypnogogic hallucinations, daily naps, and sleep attacks all showed significant improvements."	2.66	The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. ( Brown, D; Brown, L; Hirschowitz, J; Scharf, MB; Woods, M, 1985)
"Cataplexy was not affected by amphetamine treatment, but was abolished in two patients when clomipramine was given together with either amphetamine."	2.64	Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy. ( Fenton, GW; Parkes, JD, 1973)
"Amphetamine was discovered over 100 years ago."	2.49	Amphetamine, past and present--a pharmacological and clinical perspective. ( Gosden, J; Heal, DJ; Nutt, DJ; Smith, SL, 2013)
"Narcolepsy is a disabling disease with a prevalence of 0."	2.44	Pediatric narcolepsy. ( Husain, AM; Peterson, PC, 2008)
"Amphetamines evaluated were D- and D,L-amphetamine and methamphetamine."	2.43	NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. ( , 2005)
" Data obtained from a screening questionnaire, sleep diaries, and medical records showed that 22 of our 43 treated narcoleptic subjects reduced their dosage of stimulant medications or had not taken any stimulant medications during a 24-hour monitoring period during which they were expected to be on medication."	1.30	Compliance with stimulant medications in patients with narcolepsy. ( Aldrich, MS; Berrios, AM; Rogers, AE; Rosenberg, RS, 1997)
"Selegiline was compared to no treatment (7 subjects) or conventional central stimulant drugs, including dexamphetamine or mazindol (14 subjects)."	1.27	Selegiline in narcolepsy. ( Jenner, P; Langdon, N; Lock, CB; Parkes, JD; Roselaar, SE, 1987)

Research

Studies (47)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Epworth Sleepiness Score (ESS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	23 (48.94)	18.7374
1990's	8 (17.02)	18.2507
2000's	8 (17.02)	29.6817
2010's	6 (12.77)	24.3611
2020's	2 (4.26)	2.80

Authors	Studies
Morselli, F	1
Fang, L	1
Ambrosini, I	1
Chowienczyk, PJ	1
Faconti, L	1
Sivam, S	1
Chamula, K	1
Swieca, J	1
Frenkel, S	1
Saini, B	1
Kim, P	1
During, E	1
Miglis, M	1
Heal, DJ	1
Smith, SL	1
Gosden, J	1
Nutt, DJ	1
Krishnamurthy, VB	1
Nallamothu, V	1
Singareddy, R	1
Fujiki, N	1
Cheng, T	1
Yoshino, F	1
Nishino, S	1
Garg, V	1
Mahdavi, A	1
Raghavan, S	1
Quinnell, TG	1
Smith, IE	1
Christine, CW	1
Marks, WJ	1
Ostrem, JL	1
Witmans, MB	1
Kirk, VG	1
SOURS, JA	1
WILLIAMSON, DM	1
Schwartz, JR	1
Feldman, NT	1
Fry, JM	1
Harsh, J	1
Wall, IF	1
Peterson, PC	1
Husain, AM	1
Chayasirisobhon, S	1
Cullis, P	1
Veeramasuneni, RR	1
Schrader, G	1
Hicks, EP	1
Regestein, QR	1
Reich, P	1
Mufson, MJ	1
Orzel, JA	1
Kales, A	1
Cadieux, RJ	1
Soldatos, CR	1
Bixler, EO	1
Schweitzer, PK	1
Prey, WT	1
Vela-Bueno, A	1
Mitler, MM	2
Guilleminault, C	1
Parkes, JD	5
Dahlitz, M	1
Rogers, AE	1
Aldrich, MS	1
Berrios, AM	1
Rosenberg, RS	1
Ferraro, L	1
Antonelli, T	1
O'Connor, WT	1
Tanganelli, S	1
Rambert, FA	1
Fuxe, K	1
Welling, TH	1
Williams, DM	1
Stanley, JC	1
Bramble, D	1
Wyler, AR	1
Wilkus, RJ	1
Troupin, AS	1
Ullman, KC	1
Debono, AG	1
Jenner, P	2
Walters, J	1
Briggs, GG	1
Samson, JH	1
Crawford, DJ	1
Oswald, I	1
Hajdukovic, R	1
Beyer, KL	1
Bickel, JT	1
Butt, JH	1
Leong, GB	1
Shaner, AL	1
Silva, JA	1
Roselaar, SE	1
Langdon, N	1
Lock, CB	1
Scharf, MB	1
Brown, D	1
Woods, M	1
Brown, L	1
Hirschowitz, J	1
Fenton, GW	1
Fenton, G	1
Struthers, G	1
Curzon, G	1
Kantamaneni, BD	1
Buxton, BH	1
Record, C	1
Knecht, CD	1
Oliver, JE	1
Redding, R	1
Selcer, R	1
Johnson, G	1
Ellinwood, EH	1
Cohen, S	1
Yoss, RE	2
Daly, DD	1
Moyer, NJ	1
Ogle, KN	1
Mattson, RH	1
Calverley, JR	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder[NCT03337646]	Phase 4	48 participants (Actual)	Interventional	2018-09-26	Active, not recruiting
Treating Comorbid Depression of Patients With Narcolepsy by Intermittent Theta Burst Stimulation: A Preliminary Study[NCT05884112]		105 participants (Anticipated)	Interventional	2023-02-22	Recruiting
Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea[NCT01196117]		18 participants (Actual)	Interventional	2004-11-15	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Epworth Sleepiness Score (ESS) is a scale to assess sleepiness during waking hours. The scale ranges from 0-24 with higher scores indicative of greater sleepiness. (NCT01196117)
Timeframe: Difference between Baseline(Day 0) and Average of Day 1,7,14.

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~ 7am, Day 7

Intervention	units on a scale (Median)
14 Days of Placebo Therapy, Then CPAP	10.7
14 Days of CPAP Therapy	8.9

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 7am

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 0

Intervention	nmol/l (Mean)
CPAP>= 3 Hours Per Night	9.9
CPAP<3 Hours Per Night	13.3

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 11pm

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 1

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	3.2
CPAP<3 Hours Per Night	1.2

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 11pm

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 14

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	2.2
CPAP<3 Hours Per Night	1.8

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 11pm

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~11pm, Day 7

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	1.9
CPAP<3 Hours Per Night	2.2

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 11pm

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~7am, Day 0

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	3.0
CPAP<3 Hours Per Night	2.5

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 7am

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~7am, Day 1

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	12.5
CPAP<3 Hours Per Night	12.1

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 7am

Salivary Cortisol in Participants Who Used Continuous Positive Airway Pressure (CPAP) at ~7am, Day 14

Intervention	nmol/l (Median)
CPAP>= 3 Hours Per Night	7.4
CPAP<3 Hours Per Night	13.6

Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 7am

Article	Year
Amphetamine, past and present--a pharmacological and clinical perspective. Journal of psychopharmacology (Oxford, England), 2013, Volume: 27, Issue:6 Topics: Adolescent; Adult; Amphetamine; Amphetamine-Related Disorders; Animals; Attention Deficit Disorder w	2013
NARCOLEPSY AND OTHER DISTURBANCES IN THE SLEEP-WAKING RHYTHM: A STUDY OF 115 CASES WITH REVIEW OF THE LITERATURE. The Journal of nervous and mental disease, 1963, Volume: 137 Topics: Black People; Cataplexy; Craniocerebral Trauma; Depression; Dextroamphetamine; Encephalitis; Halluci	1963
Managing excessive daytime sleepiness in adults. Drug and therapeutics bulletin, 2004, Volume: 42, Issue:7 Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Dextroamphetamine; Disorders of Exce	2004
NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. NTP CERHR MON, 2005, Issue:16 Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Central Nervo	2005
Pediatric narcolepsy. Brain & development, 2008, Volume: 30, Issue:10 Topics: Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Child; Dextroamphetamine; Ghreli	2008

Article	Year
Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants. Sleep medicine, 2003, Volume: 4, Issue:1 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Dextroamphetamine;	2003
Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep, 1991, Volume: 14, Issue:3 Topics: Adult; Arousal; Benzhydryl Compounds; Central Nervous System Stimulants; Codeine; Dextroamphetamine;	1991
The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:6 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Cataplexy; Clinical Trials as Topic; Dextroamphetamin	1985
Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy. Journal of neurology, neurosurgery, and psychiatry, 1973, Volume: 36, Issue:6 Topics: Adult; Amphetamine; Antidepressive Agents; Cataplexy; Dextroamphetamine; Electroencephalography; Eva	1973
Amphetamine abuse. Science (New York, N.Y.), 1971, Jan-29, Volume: 171, Issue:3969 Topics: Acetylcholinesterase; Aggression; Amphetamine; Animals; Antisocial Personality Disorder; Behavior, A	1971

Article	Year
Uncertain Etiology of Left Ventricular Hypertrophy in a Young Subject With Hypertension Treated With Dexamphetamine. The American journal of medicine, 2020, Volume: 133, Issue:6 Topics: Adult; Amlodipine; Antihypertensive Agents; Cardiomyopathies; Deprescriptions; Dextroamphetamine; Ec	2020
Narcolepsy management in Australia: time to wake up. The Medical journal of Australia, 2021, Volume: 215, Issue:2 Topics: Australia; Dextroamphetamine; Drug Costs; Health Expenditures; Health Services Accessibility; Humans	2021
A Case of Narcolepsy Type 2 and Postural Tachycardia Syndrome Secondary to Lesions of the Thalamus and Amygdala. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018, 03-15, Volume: 14, Issue:3 Topics: Adolescent; Adrenergic beta-Antagonists; Amphetamine; Amygdala; Central Nervous System Stimulants; D	2018
An interesting case of late age at onset of narcolepsy with cataplexy. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2014, Feb-15, Volume: 10, Issue:2 Topics: Amphetamine; Cataplexy; Central Nervous System Stimulants; Dextroamphetamine; Diagnosis, Differentia	2014
Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice. Experimental neurology, 2009, Volume: 217, Issue:1 Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Ataxin-3; Benzhydryl Compounds; Cen	2009
Dexamphetamine abuse in an elderly man. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2011, Volume: 19, Issue:2 Topics: Aged; Alcoholism; Amphetamine-Related Disorders; Anxiety Disorders; Central Nervous System Stimulant	2011
Narcolepsy, idiopathic hypersomnolence and related conditions. Clinical medicine (London, England), 2011, Volume: 11, Issue:3 Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Catalepsy; Central Nervous System Stimulants	2011
Development of Parkinson's disease in patients with Narcolepsy. Journal of neural transmission (Vienna, Austria : 1996), 2012, Volume: 119, Issue:6 Topics: Adult; Age of Onset; Antiparkinson Agents; Cataplexy; Central Nervous System Stimulants; Deep Brain	2012
Infancy onset of symptoms of narcolepsy in a child. Clinical pediatrics, 2002, Volume: 41, Issue:8 Topics: Age of Onset; Central Nervous System Stimulants; Child; Child, Preschool; Dextroamphetamine; Female;	2002
A CASE OF LONG-STANDING NARCOLEPSY IN A COALMINER. The Practitioner, 1964, Volume: 193 Topics: Cataplexy; Coal Mining; Dextroamphetamine; Drug Therapy; Humans; Narcolepsy; Sleep Wake Disorders	1964
Narcolepsy in the custodial setting. Journal of clinical forensic medicine, 2005, Volume: 12, Issue:5 Topics: Antidepressive Agents; Central Nervous System Stimulants; Depression; Dextroamphetamine; Forensic Me	2005
Occurrence of neuroleptic malignant syndrome in a narcoleptic patient. Hospital & community psychiatry, 1983, Volume: 34, Issue:6 Topics: Adult; Antipsychotic Agents; Catatonia; Dextroamphetamine; Diagnosis, Differential; Humans; Male; Na	1983
Narcolepsy, paranoid psychosis, major depression, and tardive dyskinesia. The Journal of nervous and mental disease, 1984, Volume: 172, Issue:7 Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Dextroamphetamine; Dyskinesi	1984
Narcolepsy: an initial clinical approach. The Journal of clinical psychiatry, 1983, Volume: 44, Issue:5 Topics: Adult; Antidepressive Agents; Dextroamphetamine; Female; Humans; Male; Medical History Taking; Methy	1983
Acute myocardial infarction complicated by chronic amphetamine use. Archives of internal medicine, 1982, Volume: 142, Issue:3 Topics: Dextroamphetamine; Humans; Male; Middle Aged; Myocardial Infarction; Narcolepsy	1982
Narcolepsy-cataplexy. I. Clinical and electrophysiologic characteristics. Archives of neurology, 1982, Volume: 39, Issue:3 Topics: Adolescent; Adult; Aged; Catalepsy; Dextroamphetamine; Electroencephalography; Female; Hallucination	1982
Evaluation of treatment with stimulants in narcolepsy. Sleep, 1994, Volume: 17, Issue:8 Suppl Topics: Adult; Dextroamphetamine; Dose-Response Relationship, Drug; Female; Humans; Male; Methamphetamine; M	1994
Amphetamines and narcolepsy: use of the Stanford database. Sleep, 1993, Volume: 16, Issue:3 Topics: Adult; Amphetamines; Blood Pressure; Databases, Factual; Dextroamphetamine; Drug Administration Sche	1993
Amphetamine prescription. Sleep, 1993, Volume: 16, Issue:3 Topics: Amphetamines; Arousal; Dextroamphetamine; Drug Administration Schedule; Drug Prescriptions; Drug Tol	1993
Compliance with stimulant medications in patients with narcolepsy. Sleep, 1997, Volume: 20, Issue:1 Topics: Adolescent; Adult; Central Nervous System Stimulants; Dextroamphetamine; Female; Humans; Male; Methy	1997
Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biological psychiatry, 1997, Dec-15, Volume: 42, Issue:12 Topics: Animals; Benzhydryl Compounds; Biogenic Amines; Central Nervous System Stimulants; Dextroamphetamine	1997
Excessive oral amphetamine use as a possible cause of renal and splanchnic arterial aneurysms: a report of two cases. Journal of vascular surgery, 1998, Volume: 28, Issue:4 Topics: Administration, Oral; Adult; Aneurysm; Dextroamphetamine; Humans; Male; Middle Aged; Narcolepsy; Obe	1998
Psychostimulants and psychiatrists: the Trent Adult Psychiatry Psychostimulant Survey. Journal of psychopharmacology (Oxford, England), 2000, Volume: 14, Issue:1 Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Attitude of Health Personnel; Cent	2000
Editorial: Narcolepsy and cataplexy. Lancet (London, England), 1975, Apr-12, Volume: 1, Issue:7911 Topics: Brain; Catalepsy; Catecholamines; Clomipramine; Dextroamphetamine; Humans; Metabolism, Inborn Errors	1975
Methysergide in the treatment of narcolepsy. Archives of neurology, 1975, Volume: 32, Issue:4 Topics: Adult; Cataplexy; Dextroamphetamine; Electroencephalography; Electromyography; Electrooculography; F	1975
Narcolepsy and schizophrenia. The American journal of psychiatry, 1977, Volume: 134, Issue:7 Topics: Amitriptyline; Dextroamphetamine; Humans; Male; Middle Aged; Narcolepsy; Schizophrenia	1977
Amphetamines, growth hormone and narcolepsy. British journal of clinical pharmacology, 1977, Volume: 4, Issue:3 Topics: Adult; Aged; Amphetamine; Arousal; Clomipramine; Dextroamphetamine; Drug Interactions; Drug Toleranc	1977
Lack of abnormalities in a newborn exposed to amphetamine during gestation. American journal of diseases of children (1960), 1975, Volume: 129, Issue:2 Topics: Abnormalities, Drug-Induced; Adult; Apgar Score; Dextroamphetamine; Female; Fetus; Humans; Infant, N	1975
Psychological medicine. Sleep difficulties. British medical journal, 1975, Mar-08, Volume: 1, Issue:5957 Topics: Aging; Beverages; Dextroamphetamine; Dreams; Female; Humans; Hypnotics and Sedatives; Male; Mental D	1975
Ischemic colitis associated with dextroamphetamine use. Journal of clinical gastroenterology, 1991, Volume: 13, Issue:2 Topics: Colitis; Colon; Dextroamphetamine; Humans; Intestinal Mucosa; Ischemia; Male; Middle Aged; Narcoleps	1991
Narcolepsy, paranoid psychosis, and analeptic abuse. Psychiatric journal of the University of Ottawa : Revue de psychiatrie de l'Universite d'Ottawa, 1989, Volume: 14, Issue:3 Topics: Adult; Dextroamphetamine; Dose-Response Relationship, Drug; Humans; Male; Methylphenidate; Middle Ag	1989
Selegiline in narcolepsy. Sleep, 1987, Volume: 10, Issue:5 Topics: Adult; Affect; Aged; Cataplexy; Dextroamphetamine; Humans; Male; Mazindol; Middle Aged; Narcolepsy;	1987
Narcolepsy and cataplexy. Clinical features, treatment and cerebrospinal fluid findings. The Quarterly journal of medicine, 1974, Volume: 43, Issue:172 Topics: Adult; Amphetamine; Aspartic Acid; Body Weight; Cataplexy; Cerebrospinal Fluid Proteins; Dextroamphe	1974
Narcolepsy in a dog and a cat. Journal of the American Veterinary Medical Association, 1973, Jun-15, Volume: 162, Issue:12 Topics: Animals; Brain; Cat Diseases; Cats; Dextroamphetamine; Dog Diseases; Dogs; Electroencephalography; H	1973
On the treatment of narcolepsy. The Medical clinics of North America, 1968, Volume: 52, Issue:4 Topics: Dextroamphetamine; Feeding and Eating Disorders; Humans; Methamphetamine; Methylphenidate; Narcoleps	1968
The pupillogram and narcolepsy. A method to measure decreased levels of wakefulness. Neurology, 1969, Volume: 19, Issue:10 Topics: Adult; Circadian Rhythm; Dextroamphetamine; Female; Humans; Male; Methamphetamine; Middle Aged; Narc	1969
Dextroamphetamine-sulfate-induced dyskinesias. JAMA, 1968, Apr-29, Volume: 204, Issue:5 Topics: Child; Child Behavior Disorders; Child, Preschool; Dextroamphetamine; Female; Humans; Male; Middle A	1968

dextroamphetamine and Narcolepsy